🚨It’s monday & we have another FDA approval – Vivek Subbiah

🚨It’s monday & we have another FDA approval

👉FDA approves dostarlimab-gxly with chemotherapy for endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high (MSI-H).
👉Read our paper just published in  Cell Press Journal Trends in Cancer on “Tumor-agnostic drug development in dMMR/MSI-H solid tumors”.

Link to paper: Click here

👉Link to FDA approval in tumor specific endometrial context: Click here

Source: Vivek Subbiah / Linkedin